Abstract

Cellular DNA damage caused by reactive oxygen species is repaired by the base excision repair (BER) pathway which includes the DNA glycosylase MUTYH. Inherited biallelic MUTYH mutations cause predisposition to colorectal adenomas and carcinoma. However, the mechanistic progression from germline MUTYH mutations to MUTYH-Associated Polyposis (MAP) is incompletely understood. Here, we sequence normal tissue DNAs from 10 individuals with MAP. Somatic base substitution mutation rates in intestinal epithelial cells were elevated 2 to 4-fold in all individuals, except for one showing a 31-fold increase, and were also increased in other tissues. The increased mutation burdens were of multiple mutational signatures characterised by C > A changes. Different mutation rates and signatures between individuals are likely due to different MUTYH mutations or additional inherited mutations in other BER pathway genes. The elevated base substitution rate in normal cells likely accounts for the predisposition to neoplasia in MAP. Despite ubiquitously elevated mutation rates, individuals with MAP do not display overt evidence of premature ageing. Thus, accumulation of somatic mutations may not be sufficient to cause the global organismal functional decline of ageing.

Inherited mutations in MUTYH have been shown to predispose patients to colorectal cancers. Here, the authors show that MUTYH mutations lead to an increased somatic base substitution mutation rate in normal intestinal epithelial cells, which is the likely cause for the increased cancer risk.

Details

Title
Inherited MUTYH mutations cause elevated somatic mutation rates and distinctive mutational signatures in normal human cells
Author
Robinson, Philip S. 1   VIAFID ORCID Logo  ; Thomas, Laura E. 2   VIAFID ORCID Logo  ; Abascal, Federico 3   VIAFID ORCID Logo  ; Jung, Hyunchul 3 ; Harvey, Luke M. R. 3 ; West, Hannah D. 4 ; Olafsson, Sigurgeir 3 ; Lee, Bernard C. H. 5 ; Coorens, Tim H. H. 3   VIAFID ORCID Logo  ; Lee-Six, Henry 3   VIAFID ORCID Logo  ; Butlin, Laura 4   VIAFID ORCID Logo  ; Lander, Nicola 4 ; Truscott, Rebekah 4 ; Sanders, Mathijs A. 6 ; Lensing, Stefanie V. 3 ; Buczacki, Simon J. A. 7 ; ten Hoopen, Rogier 8   VIAFID ORCID Logo  ; Coleman, Nicholas 9 ; Brunton-Sim, Roxanne 10 ; Rushbrook, Simon 11 ; Saeb-Parsy, Kourosh 12   VIAFID ORCID Logo  ; Lalloo, Fiona 13 ; Campbell, Peter J. 3 ; Martincorena, Iñigo 3   VIAFID ORCID Logo  ; Sampson, Julian R. 4 ; Stratton, Michael R. 3   VIAFID ORCID Logo 

 Wellcome Sanger Institute, Cancer, Ageing and Somatic Mutation (CASM), Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); University of Cambridge, Department of Paediatrics, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934) 
 Swansea University, Institute of Life Science, Swansea, UK (GRID:grid.4827.9) (ISNI:0000 0001 0658 8800) 
 Wellcome Sanger Institute, Cancer, Ageing and Somatic Mutation (CASM), Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382) 
 Cardiff University School of Medicine, Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff, UK (GRID:grid.5600.3) (ISNI:0000 0001 0807 5670) 
 Wellcome Sanger Institute, Cancer, Ageing and Somatic Mutation (CASM), Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); The University of Hong Kong, Queen Mary Hospital, Hereditary Gastrointestinal Cancer Genetic Diagnosis Laboratory, Department of Pathology, Pokfulam, Hong Kong (GRID:grid.415550.0) (ISNI:0000 0004 1764 4144) 
 Wellcome Sanger Institute, Cancer, Ageing and Somatic Mutation (CASM), Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Erasmus University Medical Centre, Department of Haematology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X) 
 University of Oxford, Nuffield Department of Surgical Sciences, Medical Sciences Division, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Cambridge, Department of Oncology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934) 
 University of Cambridge, Department of Pathology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (GRID:grid.24029.3d) (ISNI:0000 0004 0383 8386) 
10  Norfolk and Norwich University Hospital, Norwich, UK (GRID:grid.416391.8) (ISNI:0000 0004 0400 0120) 
11  Norfolk and Norwich University Hospital, Norwich, UK (GRID:grid.416391.8) (ISNI:0000 0004 0400 0120); University of East Anglia, Norwich Medical School, Norwich, UK (GRID:grid.8273.e) (ISNI:0000 0001 1092 7967) 
12  University of Cambridge, Department of Surgery, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Cambridge Biomedical Campus, Cambridge NIHR Biomedical Research Centre, Cambridge, UK (GRID:grid.5335.0) 
13  Saint Mary’s Hospital, Manchester Centre for Genomic Medicine, Manchester, UK (GRID:grid.416523.7) (ISNI:0000 0004 0641 2620) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2686426254
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.